Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinson...( LOS ANGELES Feb. 16 /- Scientists...),Health

LOS ANGELES, Feb. 16 /PRNewswire/ -- Scientists announced today the publication of a landmark peer-reviewed paper in the February issue of the Bentham Open Stem Cell Journal which outlines the long term results of the world's first clinical trial using autologous neural stem cells for the treatment of Parkinson's disease. According to lead author, Michel F. Levesque, MD, FRCS(C), FACS, "We have documented the first successful adult neural stem cell transplantation to reverse the effects of Parkinson's disease and demonstrated the long term safety and therapeutic effects of this approach." Dr Levesque is a principal investigator for NeuroGeneration, a biotechnology company, and is affiliated with the UCLA School of Medicine and the Brain Research Institute.

The researcher reports that the publication of the article, "Therapeutic Microinjection of Autologous Adult Human Neural Stem Cells and Differentiated Neurons for Parkinson's Disease: Five-Year Post-Operative Outcome" in the Bentham Open Stem Cell Journal heralds an important moment in regenerative and personalized medicine. "Our paper describes how we were able to isolate patient-derived neural stem cells, multiply them in vitro and ultimately differentiate them to produce mature neurons before they are reintroduced into the brain's basal ganglia. This is performed without the patient requiring immunosuppressants. Of particular note are the striking results this study yielded -- for the five years following the procedure the patient's motor scales improved by over 80% for at least 36 months. A word of caution must be added however, since this is a single case study, a larger clinical trial is needed to replicate these findings," says Levesque.

"We have been pioneering the use of neural stem cells for neurodegenerative disorders since 1998 and were the first research team to successfully use differentiated adult neural stem cells for the cellular rest
'/>"/>